What is Immunome's financing cash flow?

Immunome (IMNM) reported financing cash flow of -$135K in Q1 2026.

How has Immunome's financing cash flow changed year-over-year?

Immunome's financing cash flow decreased by 100.1% year-over-year, from $162.23M to -$135K.

What is the long-term trend for Immunome's financing cash flow?

Over 3 years (2021 to 2025), Immunome's financing cash flow has grown at a 184.0% compound annual growth rate (CAGR), from $27.96M to $640.41M.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Immunome IMNM Financing Cash Flow

Financing Cash Flow at other companies

PfizerPFE

-$2.86B+45.4%

Arcus BiosciencesRCUS

$3M-97.9%

Nuvation BioNUVB

$44K-92.0%

SELLAS Life Sciences Group, Inc.SLS

$44.15M+87.2%

ArriVent BioPharma, Inc.AVBP

$54.87M+712%

IDEAYA Biosciences, Inc.IDYA

$1.18M-95.5%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's financing cash flow?: Immunome (IMNM) reported financing cash flow of -$135K in Q1 2026.
How has Immunome's financing cash flow changed year-over-year?: Immunome's financing cash flow decreased by 100.1% year-over-year, from $162.23M to -$135K.
What is the long-term trend for Immunome's financing cash flow?: Over 3 years (2021 to 2025), Immunome's financing cash flow has grown at a 184.0% compound annual growth rate (CAGR), from $27.96M to $640.41M.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.